Oscar Health (NYSE:OSCR) Price Target Cut to $45.00 by Analysts at Piper Sandler

Oscar Health (NYSE:OSCR) had its target price decreased by research analysts at Piper Sandler from $48.00 to $45.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler‘s price target would indicate a potential upside of 35.74% from the stock’s previous close.

A number of other equities analysts have also commented on the company. Bank of America raised their price objective on Oscar Health from $28.00 to $30.00 and gave the stock an “underperform” rating in a research note on Thursday, September 17th. Robert W. Baird upped their target price on Oscar Health from $27.00 to $33.00 and gave the company a “neutral” rating in a research report on Thursday, September 17th. Wells Fargo & Company increased their price objective on shares of Oscar Health from $20.00 to $27.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 13th. Raymond James Financial raised their target price on shares of Oscar Health from $34.00 to $42.00 and gave the company an “outperform” rating in a report on Friday, September 18th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $34.00 price target on shares of Oscar Health in a research note on Thursday, September 17th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $34.60.

Oscar Health Stock Down 5.8%

Oscar Health stock opened at $33.15 on Friday. The company’s 50-day moving average price is $31.80 and its two-hundred day moving average price is $23.89. The stock has a market cap of $10.23 billion, a P/E ratio of 23.68, a P/E/G ratio of 0.39 and a beta of 2.56. Oscar Health has a twelve month low of $10.69 and a twelve month high of $38.50. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.21.

Oscar Health (NYSE:OSCR) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.63. Oscar Health had a net margin of 3.60% and a return on equity of 38.45%. The business had revenue of $5.14 billion for the quarter, compared to analyst estimates of $4.69 billion. During the same period last year, the firm earned ($0.53) earnings per share. Oscar Health’s revenue for the quarter was up 72.1% compared to the same quarter last year. As a group, analysts expect that Oscar Health will post 1.83 EPS for the current year.

Insiders Place Their Bets

In other Oscar Health news, CAO Victoria Baltrus sold 958 shares of the stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $31.45, for a total transaction of $30,129.10. Following the completion of the sale, the chief accounting officer owned 213,631 shares of the company’s stock, valued at approximately $6,718,694.95. This represents a 0.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam Mcananey sold 9,092 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $31.45, for a total transaction of $285,943.40. Following the sale, the insider owned 209,004 shares of the company’s stock, valued at approximately $6,573,175.80. This trade represents a 4.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 874,451 shares of company stock valued at $26,761,671 over the last three months. Insiders own 22.64% of the company’s stock.

Institutional Investors Weigh In On Oscar Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Fifth Third Bancorp grew its holdings in Oscar Health by 67.9% during the third quarter. Fifth Third Bancorp now owns 152,121 shares of the company’s stock worth $4,691,000 after buying an additional 61,544 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in Oscar Health by 4.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 31,941 shares of the company’s stock valued at $955,000 after buying an additional 1,339 shares during the last quarter. Alps Advisors Inc. bought a new position in Oscar Health during the 3rd quarter valued at $529,000. Kestra Private Wealth Services LLC bought a new position in Oscar Health during the 3rd quarter valued at $245,000. Finally, XML Financial LLC purchased a new position in Oscar Health during the 3rd quarter worth $303,000. 75.70% of the stock is owned by institutional investors.

Trending Headlines about Oscar Health

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Oscar reported Q3 adjusted earnings of $0.49 per share, versus expectations for a loss, and revenue of $5.14 billion, above the $4.69 billion consensus and up 72.1% year over year. The company also recorded a $167.3 million profit, while membership rose 27.2% to 2.69 million and its medical loss ratio improved to 84%. Oscar Health Q3 2026: A Surprise Profit and Its Third Guidance Raise
• Positive Sentiment: Management raised its 2026 revenue outlook for the third time, to $19 billion–$19.3 billion, above FactSet’s $18.64 billion estimate. The higher forecast signals stronger expected sales than analysts had anticipated. Oscar Health 2026 Revenue Outlook
• Positive Sentiment: Zacks added OSCR to its Rank #1 (Strong Buy) growth-stocks list, adding a favorable analyst-screening signal. Best Growth Stocks to Buy for November 6th
• Neutral Sentiment: Despite the earnings beat and stronger outlook, one report said Oscar shares slipped as other healthcare stocks rose. That points to a mixed immediate reaction, rather than a clear deterioration in the company’s reported results. Oscar slips as LifeStance, HCA climb on earnings, payment hike

About Oscar Health

Oscar Health, Inc is a technology-focused health insurance company that provides health plans and related services in the United States. The company primarily serves individuals and families purchasing coverage through the Affordable Care Act’s health insurance marketplace, as well as small businesses and their employees.

Oscar combines health insurance products with digital tools designed to help members manage their care. Its services include online enrollment, virtual care, provider search and appointment support, care navigation, claims and benefits information, and member engagement through web and mobile applications.